Mizoribine provides effective treatment of sequential histological change of arteritis and reduction of inflammatory cytokines and chemokines in an animal model of Kawasaki disease

January 2011
Pediatric Rheumatology;2011, Vol. 9 Issue 1, p30
Academic Journal
The article presents a research which examines the effectiveness of immunosuppressive drug mizoribine (MZR), for treatment of Kawasaki disease (KD). It is stated that 16.5 percent of KD patients remain unresponsive to intravenous immunoglobulin (IVIg) treatment. In this research, MZR was studied in a mouse model of KD, by administering MZR or IgG for 5 days, then examining for cytokines, chemokines and incidence of panvasculitis in IVg and MZR groups. Results showed that panvasculitis decreased by 50 percent, and inflammatory chemokines and cytokines were suppressed in MZR group, while in both groups severity of inflammation was decreased. It can be concluded from this study that MZR treatment might be useful for KD treatment.


Related Articles

  • Comparison of High-Dose and Low0Dose Aspirin Plus Intravenous Immunoglobulin in the treatment of Kawasaki Syndrome. Saulsbury, Frank T. // Clinical Pediatrics;Oct2002, Vol. 41 Issue 8, p597 

    The efficacy of intravenous immunoglobulin (IVIG) in the treatment of Kawasaki syndrome (KS) has been unequivocally established, but questions remain concerning the proper dose of adjunctive aspirin therapy in the treatment of KS. The medical records of 72 children with KS were reviewed. All...

  • Pharmacological Therapy for Patients with Kawasaki Disease. Williams, R.V.; Minich, L.L.; Tani, L.Y. // Pediatric Drugs;2001, Vol. 3 Issue 9, p649 

    Kawasaki disease is a systemic vasculitis of unknown aetiology that has been reported worldwide since its initial description in Japanese children. The most significant sequelae of acute Kawasaki disease are related to the inflammation of small to medium sized arteries and, in particular, the...

  • Reconsidering steroids in Kawasaki disease management. Burke, Michael G. // Contemporary Pediatrics;Sept2003, Vol. 20 Issue 9, p16 

    Discusses a study on the effectivity of adding corticosteroid agent to intravenous (IV) immunoglobulin in treating Kawasaki disease. Number of children who were treated with IV methylprednisolone (IVMP); Mean duration of fever of children from IVMP group; Results of the study.

  • A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. Sakata, Koichi; Hamaoka, Kenji; Ozawa, Sei-ichiro; Niboshi, Ayumi; Yoshihara, Takao; Nishiki, Tesuo; Nakagawa, Yumi; Kazuta, Kikuko; Morimoto, Yoshiko; Kamiya, Yasutaka; Yamamoto, Toru; Horii, Yoshihiro; Kido, Sachiko // European Journal of Pediatrics;Jun2007, Vol. 166 Issue 6, p565 

    A single, 2 g/kg dose of immune globulin (IG), denoted 2 g-intravenous (IV)IG, has become a standard regimen for treating Kawasaki disease (KD) because of its highly preventive effect on coronary arterial lesions (CAL). However, IG is obtained from blood specimens, a drawback to many patients,...

  • Increased Incidence of Incomplete Kawasaki Disease at a Pediatric Hospital After Publication of the 2004 American Heart Association Guidelines. Ghelani, Sunil; Sable, Craig; Wiedermann, Bernhard; Spurney, Christopher // Pediatric Cardiology;Oct2012, Vol. 33 Issue 7, p1097 

    We sought to study the impact of the 2004 American Heart Association guidelines on diagnosis and treatment of patients with Kawasaki disease (KD). We reviewed patient records from July 2000 to June 2002 (group 1) and July 2007 to June 2009 (group 2) at a tertiary children's hospital. The...

  • Management of Kawasaki disease. Eleftheriou, D.; Levin, M.; Shingadia, D.; Tulloh, R.; Klein, N. J.; Brogan, P. A. // Archives of Disease in Childhood;Jan2014, Vol. 99 Issue 1, p74 

    Kawasaki disease (KD) is an acute self-limiting inflammatory disorder, associated with vasculitis, affecting predominantly medium-sized arteries, particularly the coronary arteries. In developed countries KD is the commonest cause of acquired heart disease in childhood. The aetiology of KD...

  • Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease. Okada, Keiko; Hara, Junichi; Maki, Ichiro; Miki, Kazunori; Matsuzaki, Kouji; Matsuoka, Taro; Yamamoto, Takehisa; Nishigaki, Toshinori; Kurotobi, Syunji; Sano, Tetsuya; Osaka Kawasaki Disease Study Group // European Journal of Pediatrics;Feb2009, Vol. 168 Issue 2, p181 

    Approximately 15-20% of patients with Kawasaki disease (KD) are not responsive to high-dose intravenous gammaglobulin (IVIG). We have previously reported a predictive method for identifying IVIG-non-responsive patients (high-risk KD patients). We determined the safety and effectiveness of pulse...

  • Comparative Effectiveness of Intravenous Immunoglobulin for Children with Kawasaki Disease: A Nationwide Cohort Study Lin, Ming-Chih; Fu, Yun-Ching; Jan, Sheng-Ling; Lai, Mei-Shu // PLoS ONE;May2013, Vol. 8 Issue 5, p1 

    Introduction: Different immunoglobulin manufacturing processes may influence its effectiveness for Kawasaki disease. However, nationwide studies with longitudinal follow-up are still lacking. The aim of this study was to evaluate the comparative effectiveness of immunoglobulin preparations from...

  • Variations in the Number of CCL3L1 Gene Copies and Kawasaki Disease in Korean Children. Kim, Hye-Eun; Kim, Jae-Jung; Han, Myung; Lee, Kyung-Yil; Song, Min; Lee, Hyoung-Doo; Kim, Dong; Yu, Jeong; Park, In-Sook; Yun, Sin; Hong, Young; Jang, Gi; Lee, Jong-Keuk // Pediatric Cardiology;Dec2012, Vol. 33 Issue 8, p1259 

    High-dose intravenous immunoglobulin (IVIG) therapy is the highly effective and standard treatment for Kawasaki disease (KD). However, ~20 % of KD patients have persistent fever or recurrence of fever after the initial IVIG treatment, which increases the risk for coronary artery lesions (CALs)....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics